Supernus Pharmaceuticals | SUPN - Equity Capital And Reserves


Supernus Pharmaceuticals reported $1.08B in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
Abbott USD 52.06B 69M Mar/2026
ANI Pharmaceuticals USD 562.3M 21.58M Mar/2026
Aurora Cannabis CAD 511.83M 24.53M Mar/2026
Bristol-Myers Squibb USD 20.07B 1.6B Mar/2026
Canopy Growth CAD 697.59M 60.58M Mar/2026
Cara Therapeutics USD 20.95M 6.92M Dec/2025
Corcept Therapeutics USD 637.99M 9.82M Mar/2026
Eisai JPY 898.99B 9.36B Mar/2026
Eli Lilly USD 31.2B 4.66B Mar/2026
Novo Nordisk DKK 203.07B 9.02B Mar/2026
Pacira USD 653.89M 39.22M Mar/2026
Perrigo USD 2.5B 436.7M Mar/2026
Pfizer USD 90.1B 3.63B Mar/2026
Supernus Pharmaceuticals USD 1.08B 15.09M Mar/2026
United Therapeutics USD 5.9B 1.2B Mar/2026
Xeris Pharmaceuticals USD 13.01M 678K Mar/2026